heterogeneous nuclear ribonucleoprotein C pseudogene 8Genealiases: []
Q-omics provides the consensus-scored HNRNPCP8 profile across patient tissues and cancer cell-line models. HNRNPCP8 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HNRNPCP8 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, HNRNPCP8 RNA expression shows 6,796 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight SKCM, KIRC, and STAD as cancer lineages where HNRNPCP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HNRNPCP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HNRNPCP8 survival associations across molecular data types. HNRNPCP8 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HNRNPCP8 RNA expression–survival associations across cancer types. High HNRNPCP8 expression shows unfavorable associations in ACC, LIHC, PCPG and PAAD, but favorable associations in SKCM and COAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for HNRNPCP8 RNA expression.
This table summarizes HNRNPCP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HNRNPCP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HNRNPCP8 shows higher tumor expression in KIRC, HNSC, KIRP, LIHC, CHOL and LUAD. The KIRC box plot shows higher HNRNPCP8 RNA expression in tumor versus normal tissue (log2 FC = +0.095, t-test p < 0.001).
This table shows molecular features associated with HNRNPCP8 in patient tissues and cancer cell lines. In patient samples, HNRNPCP8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
